MITF and melanoma: Our observation of lower proportions of MITF+ melanoma cells in patients’ metastatic lesions taken after immunotherapy compared to pre-therapy supports the hypothesis of a more efficient targeting of these cells by therapy-induced immune response, while AXL+ melanoma cells may be more resistant.